亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Antimicrobial lipopeptides and their uses II

總結: New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. These novel lipopeptide antibiotics have demonstrated superior in vivo efficacy and toxicity overcurrent polymyxin antibiotics.

技術優勢: - Novel lipopeptide antibiotics that target multidrug-resistant Gram- negative bacteria
- Greater efficacy and significantly less nephrotoxicity in animal models than currently available Polymyxin B drugs and Colistin
- Potential for administration via intravenous, inhaled or topical routes

詳細技術說明: Using their polymyxin drug discovery platform, researchers from the Monash Institute of Pharmaceutical Sciences have identified a series of proprietary Polymyxin analogues that are active against Gram-negative ‘superbugs’.

The Monash researchers have completed in vivo efficacy and toxicity evaluations of the lipopeptide antibiotics in mouse models. When compared with commercially available Polymyxin B and Colistin, the lipopeptide analogues demonstrate improved antibacterial efficacy (Figure 1) and significantly less nephrotoxicity.

其他: Monash University has extensive academic and industrial experience in medicinal chemistry, pharmacokinetics/ pharmacodynamics, and in vitro and in vivo evaluations of antibiotics. Monash seeks a partner to complete advanced IND-enabling preclinical assessment of its lead candidate lipopeptide and to undertake clinical development.

欲了解更多信息，請點擊這裡